

COMPLETE LISTING OF CLAIMS

1. (CURRENTLY AMENDED) A method ~~to aid in detecting of assessing~~ a predisposition in an individual to ~~developing~~ ~~presenting~~ preeclampsia ~~during pregnancy~~, comprising: measuring the level of peptide in a sample of body fluid of said individual, wherein said peptide ~~consists of is selected from the group consisting of:~~ amino acid sequence set forth in SEQ ID NO:1, ~~amino acid sequence set forth in SEQ ID NO:2, and amino acid sequence set forth in SEQ ID NO:4~~ and comparing said level of peptide to a standard, wherein the standard represents the average level of said peptide in normal body fluid, and whereby a significantly lower level of said peptide in the sample correlates with magnesium binding defect and thereby indicates that said individual is at risk of developing ~~is indicative of a predisposition of said individual to preeclampsia.~~

2. (CANCELED)

3. (CURRENTLY AMENDED) The method of claim 1 wherein the level of said peptide in said sample is measured by an immunological assay that can indicate the presence of ~~one or more of~~ amino acid sequence set forth in SEQ ID NO:1, ~~or amino acid sequence set forth in SEQ ID NO:2, or amino acid sequence set forth in SEQ ID NO:4.~~

4. (ORIGINAL) The method of claim 3 wherein said immunological assay utilizes a monoclonal antibody.

5. (ORIGINAL) The method of claim 4 wherein said monoclonal antibody cross reacts with each of said peptides.

6. (ORIGINAL) The method of claim 3 wherein said immunological assay is an enzyme-linked immunosorbent assay, and said sample of body fluid is blood.

7. (CANCELED)

8. (CANCELED)
9. (CANCELED)
10. (CANCELED)
11. (CANCELED)
12. (CANCELED)
13. (CANCELED)
14. (CANCELED)
15. (CANCELED)
16. (CANCELED)
17. (CANCELED)
18. (CANCELED)
19. (CURRENTLY AMENDED) A method for monitoring progress in treatment of preeclampsia in an individual, comprising:
 - a. measuring the level of peptide in a sample of body fluid of said individual, wherein said peptide is selected from the group consisting of: amino acid sequence set forth in SEQ ID NO:1, amino acid sequence set forth in SEQ ID NO:2, and amino acid sequence set forth in SEQ ID NO:4;
 - b. treating preeclampsia in the individual,
 - c. repeating step a, and
 - d. comparing said level of peptide of step a, to the level of said peptide of step c,

wherein a lower than normal level of said peptide correlates with magnesium binding defect, and whereby a significant increase in the level of said peptide after treatment is indicative of the progress of treatment of said individual.

20. (CANCELED)

21. (CANCELED)

22. (CANCELED)

23. (CANCELED)

24. (CANCELED)

25. (CANCELED)

26. (CANCELED)

27. (CANCELED)

28. (CANCELED)

29. (CANCELED)

30. (CANCELED)

31. (NEW) A method to aid in detecting predisposition in an individual to developing preeclampsia, comprising: measuring the level of peptide in a sample of body fluid of said individual, wherein said peptide consists of amino acid sequence set forth in SEQ ID NO:2, and comparing said level of peptide to a standard, wherein the standard represents the average level of said peptide in normal body fluid, and whereby a significantly lower level of said peptide in the sample correlates with magnesium binding defect and thereby indicates that said individual is at risk of developing preeclampsia.

32. (NEW) The method of claim 31 wherein the level of said peptide in said sample is measured by an immunological assay that can indicate the presence of amino acid sequence set forth in SEQ ID NO:2.

33. (NEW) The method of claim 32 wherein said immunological assay utilizes a monoclonal antibody.

34. (NEW) The method of claim 33 wherein said monoclonal antibody cross reacts with each of said peptides.

35. (NEW) The method of claim 32 wherein said immunological assay is an enzyme-linked immunosorbent assay, and said sample of body fluid is blood.

36. (NEW) A method to aid in detecting predisposition in an individual to developing preeclampsia, comprising: measuring the level of peptide in a sample of body fluid of said individual, wherein said peptide consists of amino acid sequence set forth in SEQ ID NO:4, and comparing said level of peptide to a standard, wherein the standard represents the average level of said peptide in normal body fluid, and whereby a significantly lower level of said peptide in the sample correlates with magnesium binding defect and thereby indicates that said individual is at risk of developing preeclampsia.

37. (NEW) The method of claim 36 wherein the level of said peptide in said sample is measured by an immunological assay that can indicate the presence of amino acid sequence set forth in SEQ ID NO:4.

38. (NEW) The method of claim 37 wherein said immunological assay utilizes a monoclonal antibody.

39. (NEW) The method of claim 38 wherein said monoclonal antibody cross reacts with each of said peptides.

Express Mail Label No.: EV 136922582 US

Serial No.: 10/805,881

Docket No.: 800812-0005

40. (NEW) The method of claim 37 wherein said immunological assay is an enzyme-linked immunosorbent assay, and said sample of body fluid is blood.